Recent News

Athenex Announces Additional Licensing Agreements for Tirbanibulin

Athenex to Provide Corporate and Financial Update for the Second Quarter 2021 on August 5, 2021

Athenex Announces European Commission Approval of Klisyri® (tirbanibulin) for the Topical Treatment of Actinic Keratosis

Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer

Athenex Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program

Athenex Announces Klisyri® (tirbanibulin) Receives Positive CHMP Opinion from the European Medicines Agency (EMA) for the Treatment of Actinic Keratosis of the Face or Scalp

Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine Present New Clinical Data on GD2 CAR-NKT Cells in Neuroblastoma at ASGCT Annual Meeting

Athenex Provides First Quarter 2021 Corporate and Financial Update

Athenex to Acquire Kuur Therapeutics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR-NKT Platform

Our Science

We are focused on discovering and developing novel therapies for treating cancer and addressing unmet medical needs.

Learn more

Investors

View press releases, events and presentations, and other investment information

Learn more

Join Our Team

As the Company grows, we are always looking to add talented professionals to join the Athenex family.

Learn more